These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28646517)

  • 1. Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens.
    Jain P; Kantarjian H; Jain N; Short NJ; Yin CC; Kanagal-Shamanna R; Khoury J; Konopleva M; Sasaki K; Kadia TM; Garris R; Pierce S; Estrov Z; Wierda W; Cortes J; O'Brien S; Ravandi F; Jabbour E
    Am J Hematol; 2017 Oct; 92(10):E595-E597. PubMed ID: 28646517
    [No Abstract]   [Full Text] [Related]  

  • 2. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience.
    Jain P; Kantarjian H; Ravandi F; Thomas D; O'Brien S; Kadia T; Burger J; Borthakur G; Daver N; Jabbour E; Konopleva M; Cortes J; Pemmaraju N; Kelly MA; Cardenas-Turanzas M; Garris R; Faderl S
    Leukemia; 2014 Apr; 28(4):973-5. PubMed ID: 24157581
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
    Richard-Carpentier G; Jabbour E; Short NJ; Rausch CR; Savoy JM; Bose P; Yilmaz M; Jain N; Borthakur G; Ohanian M; Alvarado Y; Rytting M; Kebriaei P; Konopleva M; Kantarjian H; Ravandi F
    Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):212-218. PubMed ID: 32035785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine.
    Morita K; Jain N; Kantarjian H; Takahashi K; Fang H; Konopleva M; El Hussein S; Wang F; Short NJ; Maiti A; Sasaki K; Garcia-Manero G; Konoplev S; Ravandi F; Khoury JD; Jabbour E
    Am J Hematol; 2021 May; 96(5):589-598. PubMed ID: 33639000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyper-CVAD regimen in routine management of adult acute lymphoblastic leukemia: a retrospective multicenter study.
    Buyukasik Y; Acar K; Kelkitli E; Uz B; Serefhanoglu S; Ozdemir E; Pamukcuoglu M; Atay H; Bektas O; Sucak GT; Turgut M; Aksu S; Yagci M; Sayınalp N; Ozcebe OI; Goker H; Haznedaroglu IC
    Acta Haematol; 2013; 130(3):199-205. PubMed ID: 23797290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers.
    Alacacioglu I; Medeni SS; Ozsan GH; Payzin B; Sevindik OG; Acar C; Katgi A; Ozdemirkan F; Piskin O; Ozcan MA; Undar B; Demirkan F
    Chemotherapy; 2014; 60(4):219-23. PubMed ID: 25871894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotypic analysis of adult patients with T-cell lymphoblastic lymphoma treated with hyper-CVAD.
    Kato H; Yamamoto K; Kodaira T; Higuchi Y; Yamamoto H; Saito T; Taji H; Yatabe Y; Nakamura S; Kinoshita T
    Hematology; 2018 Mar; 23(2):83-88. PubMed ID: 28778131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
    Kanagal-Shamanna R; Jain P; Takahashi K; Short NJ; Tang G; Issa GC; Ravandi F; Garcia-Manero G; Yin CC; Luthra R; Patel KP; Khoury JD; Montalban-Bravo G; Sasaki K; Kadia TM; Borthakur G; Konopleva M; Jain N; Garris R; Pierce S; Wierda W; Estrov Z; Cortes J; O'Brien S; Kantarjian HM; Jabbour E
    Cancer; 2017 Oct; 123(19):3717-3724. PubMed ID: 28608976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
    Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
    Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of lymphomas containing Epstein-Barr virus after therapy with hyper-CVAD regimen.
    Luskin MR; Roy DB; Wasik MA; Loren AW
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e55-8. PubMed ID: 24393621
    [No Abstract]   [Full Text] [Related]  

  • 12. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian HM; O'Brien S; Smith TL; Cortes J; Giles FJ; Beran M; Pierce S; Huh Y; Andreeff M; Koller C; Ha CS; Keating MJ; Murphy S; Freireich EJ
    J Clin Oncol; 2000 Feb; 18(3):547-61. PubMed ID: 10653870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary T-cell lymphoblastic lymphoma of the cavernous sinus.
    Sadruddin S; Medeiros LJ; DeMonte F
    J Neurosurg Pediatr; 2010 Jan; 5(1):94-7. PubMed ID: 20043743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
    Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
    Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
    El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD.
    Sakhdari A; Thakral B; Loghavi S; Kanagal-Shamanna R; Yin CC; Zuo Z; Routbort MJ; Luthra R; Medeiros LJ; Wang SA; Patel KP; Ok CY
    Cancer Med; 2020 Feb; 9(3):849-858. PubMed ID: 31804006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function.
    Seshadri T; Hourigan MJ; Wolf M; Mollee PN; Seymour JF
    Leuk Res; 2006 Apr; 30(4):483-5. PubMed ID: 16171861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study.
    Gaynor ER; Unger JM; Miller TP; Grogan TM; White LA; Mills GM; Balcerzak SP; Varterasian M; LeBlanc M; Fisher RI
    J Clin Oncol; 2001 Feb; 19(3):750-5. PubMed ID: 11157027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (≥200 × 10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Group.
    Hastings C; Gaynon PS; Nachman JB; Sather HN; Lu X; Devidas M; Seibel NL
    Br J Haematol; 2015 Feb; 168(4):533-46. PubMed ID: 25308804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G80A Single Nucleotide Polymorphism in Reduced Folate Carrier-1 Gene in a Mexican Population and its Impact on Survival in Patients with Acute Lymphoblastic Leukemia.
    Candelaria M; Ojeda J; Gutiérrez-Hernández O; Taja-Chayeb L; Vidal-Millán S; Dueñas-González A
    Rev Invest Clin; 2016; 68(3):154-62. PubMed ID: 27409003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.